IP Library Granted Patent US 8,637,006
Granted Patent B2
US 8,637,006 · App. 13/471,606 · Granted Jan 28, 2014

Recombinant vaccines and use thereof

Inventors: Özlem Türeci (Mainz, DE); Ugur Sahin (Mainz, DE); Sebastian Kreiter (Mainz, DE)
Assignee: BioNTech AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,637,006
App. No.
13/471,606
Granted
Jan 28, 2014
Kind
B2
Abstract

The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.

Claims (10)

1. A nucleic acid molecule which codes for a fusion protein comprising an antigen, and a transmembrane region and a cytoplasmic region of a chain of a MHC molecule or CD1a, CD1b or CD1c but free from (i) α1, α2 and α3 domains of the α chain of a MHC Class I molecule or CD1a, CD1b or CD1c, (ii) β2-microglobulin of a MHC Class I molecule or CD1a, CD1b or CD1c, (iii) α1 and α2 domains of the α chain of a MHC Class II molecule, and (iv) β1 and β2 domains of the β chain of a MHC Class II molecule.

2. An isolated host cell which comprises the nucleic acid molecule as claimed in claim 1 .

3. A composition which comprises the nucleic acid molecule of claim 1 in a pharmaceutically acceptable carrier.

4. The nucleic acid molecule of claim 1 wherein the nucleic acid molecule encodes a fusion protein that includes an amino acid residue sequence selected from the group consisting of SEQ ID NO: 2, 4, 12, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, and 42.

5. The nucleic acid molecule of claim 1 wherein the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 11 or SEQ ID NO: 13.

6. The nucleic acid molecule of claim 1 wherein the nucleic acid molecule encodes the amino acid residue sequence of SEQ ID NO: 12.

7. The nucleic acid molecule of claim 1 wherein the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 11.

8. The nucleic acid molecule of claim 1 wherein the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 13.

9. The nucleic acid molecule of claim 1 wherein the nucleic acid molecule encodes the amino acid residue sequence of SEQ ID NO: 14.

10. A composition which comprises isolated the host cell of claim 2 .

Assignments (3)
CHANGE OF NAME Recorded Nov 8, 2019
From: BIONTECH AG
To: BIONTECH SE
Reel/Frame 051720/0542 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2018
From: TURECI, OZLEM; SAHIN, UGUR; KREITER, SEBASTIAN
To: JOHANNES GUTENBERG-UNIVERSITAT MAINZ, VERTRETEN DURCH DEN PRASIDENTEN
Reel/Frame 044909/0429 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2018
From: JOHANNES GUTENBERG-UNIVERSITAT MAINZ, VERTRETEN DURCH DEN PRASIDENTEN
To: BIONTECH AG
Reel/Frame 044909/0461 →
Priority Claims (1)
DE 103 47 710 · Oct 14, 2003 · national
Continuity (2)
Division 10575640
Related Publication 20130011426A1 · Jan 10, 2013